Clinical trial
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
NCT00030641
Study timeline
Study start (unknown)2001-10-01Date precision: month
Registry last updated2014-01-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancerunresolved
Interventions
oblimersen sodiumBIOLOGICAL
docetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Genta Incorporatedlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
DallasTexas, United States2MoscowRussia2Saint PetersburgRussia2MorgantownWest Virginia, United States2New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1AtlantaGeorgia, United States1TorontoOntario, Canada1San FranciscoCalifornia, United States1BirminghamAlabama, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00030641 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.